Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
September 15th 2022Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.
Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
February 17th 2020The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.